Prostate Cancer

Treatment with the pan-BET bromodomain inhibitor ZEN-3694 plus enzalutamide may re-sensitize patients to androgen receptor–targeting agents.

Survival outcomes are not compromised in men undergoing active surveillance, a recent study finds.

The FoundationOne Liquid CDx pan-tumor liquid biopsy examines over 300 cancer-related genes in a patient’s blood sample to inspect for deleterious alterations.

In this episode, Samuel J. Peretsman, MD, discusses how to get started with HIFU for prostate cancer and performing robotic prostatectomy following HIFU.

Focal therapy using HIFU may be offered as an alternative to the existing modalities of treatment for select patients with all risk profiles of prostate cancer.

Starting radiotherapy up to 6 months following the start of androgen-deprivation therapy was not linked to poorer overall survival outcomes.

Next-generation sequencing identifies subtypes that may benefit from immune checkpoint inhibitors.

Findings from the phase 2 TRITON2 trial, which led to the FDA approval of the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer, have been published in the Journal of Clinical Oncology.

Against the backdrop of a new guideline for advanced prostate cancer, Robert A. Dowling, MD, describes how you might measure adherence to guidelines in your own practice.

Response and survival rates with the immunotherapy-based regimen support ongoing phase 3 research with pembrolizumab in prostate cancer.

Agent shows statistically significant superiority to conventional computed tomography.

The randomized ESCALATE trial has a primary end point of symptomatic skeletal event-free survival.

Study results showed sensitivity and specificity rates above 90%.

In this episode, Samuel J. Peretsman, MD, explains what he tells patients undergoing HIFU to expect postoperatively.

The randomized trial is evaluating the combination of pembrolizumab and olaparib against abiraterone acetate or enzalutamide.

Investigators found that while patients without pain had an overall survival of 56 months, patients with pain had an overall survival of only 27 months.

Injection of an absorbable perirectal hydrogel spacer prior to radiotherapy for prostate cancer may reduce rectal irradiation and the associated rectal toxic effects that manifest clinically after longer-term follow-up.

A subgroup analysis of the pivotal phase 3 ARAMIS trial showed that the efficacy of darolutamide was sustained in patients with a rapid PSA double time.

Mediterranean diet score was modestly associated with time to grade group progression.

"This new therapy could change the landscape for the treatment of advanced prostate cancer," Thrasher writes.

“Our findings suggest that genomic score and PSA density are risk factors for upgrading within 3 years of commencing active surveillance,” the investigators wrote.

Oral GnRH receptor antagonist has “potential to become a new standard for ADT,” a study investigator says.

Referring physicians implemented PSMA PET–based treatment changes in 72% of patients.

The phase 3 SPOTLIGHT study is assessing the diagnostic capability of rhPSMA-7.3 (18F) PET in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy.

Cancers that are missed by mpMRI are significantly smaller and less aggressive than those that are detected.